Pharmaceuticals

  • Read more: The Opioid Crisis Requires Evidence-Based Solutions, Part II: How the President’s Commission on Combating Drug Addiction Ignored Promising Medical Treatments

    The Opioid Crisis Requires Evidence-Based Solutions, Part II: How the President’s Commission on Combating Drug Addiction Ignored Promising Medical Treatments

    By Mason Marks Last year more than 64,000 Americans died of drug overdose, which is “now the leading cause of death” in people under 50. Opioids kill an estimated 91 Americans each day and are responsible for most drug-related deaths in the US. This public health crisis requires solutions that are supported by science and…

  • Read more: The Opioid Crisis Requires Evidence-Based Solutions, Part I: How the President’s Commission on Combating Drug Addiction Misinterpreted Scientific Studies

    The Opioid Crisis Requires Evidence-Based Solutions, Part I: How the President’s Commission on Combating Drug Addiction Misinterpreted Scientific Studies

    By Mason Marks The opioid crisis kills at least 91 Americans each day and has far-reaching social and economic consequences for us all. As lawmakers explore solutions to the problem, they should ensure that new regulations are based on scientific evidence and reason rather than emotion or political ideology. Though emotions should motivate the creation…

  • Read more: The CVS/Aetna Deal: The Promise in Data Integration

    The CVS/Aetna Deal: The Promise in Data Integration

    By Wendy Netter Epstein Earlier this month, CVS announced plans to buy Aetna— one of the nation’s largest health insurers—in a $69 billion deal.  Aetna and CVS pitched the deal to the public largely on the promise of controlling costs and improving efficiency in their operations, which they say will inhere to the benefit of…

  • Read more: Limited Seats Still Available, Register Now! 12/12: Sixth Annual Health Law Year in P/Review

    Limited Seats Still Available, Register Now! 12/12: Sixth Annual Health Law Year in P/Review

    Health Law Year in P/Review December 12, 2017 8:30 AM – 5:00 PM Wasserstein Hall, Milstein East AB Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Register for this event The Sixth Annual Health Law Year in P/Review symposium will feature leading experts discussing major developments during 2017 and what to watch out for in 2018. The…

  • Read more: 2017’s Word Of The Year In Health Law And Bioethics: Uncertainty

    2017’s Word Of The Year In Health Law And Bioethics: Uncertainty

    By Carmel Shachar and I. Glenn Cohen This is the first post by Carmel Shachar and I. Glenn Cohen that appears on the Health Affairs Blog in a series stemming from the Sixth Annual Health Law Year in P/Review event to be held at Harvard Law School on Tuesday, December 12, 2017. 2017 was a year of tremendous uncertainty for many areas…

  • Read more: TODAY, 12/4 at 5 PM: Health Law Workshop with Rachel Sachs

    TODAY, 12/4 at 5 PM: Health Law Workshop with Rachel Sachs

    December 4, 2017 5-7 PM Hauser Hall, Room 104 Harvard Law School, 1575 Massachusetts Ave., Cambridge, MA Presentation: “Delinking Reimbursement” This paper is not available for download. To request a copy in preparation for the workshop, please contact Jennifer Minnich at jminnich@law.harvard.edu. Rachel E. Sachs is Associate Professor of Law at Washington University School of Law (St. Louis).…

  • Read more: REGISTER NOW (12/12)! Sixth Annual Health Law Year in P/Review

    REGISTER NOW (12/12)! Sixth Annual Health Law Year in P/Review

    Health Law Year in P/Review December 12, 2017 8:30 AM – 5:00 PM Wasserstein Hall, Milstein East AB Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Register for this event The Sixth Annual Health Law Year in P/Review symposium will feature leading experts discussing major developments during 2017 and what to watch out for in 2018. The…

  • Read more: Roche and City of Hope Claim Pfizer Biosimilar Version of Trastuzumab Will Infringe “At Least” 40 Patents

    Roche and City of Hope Claim Pfizer Biosimilar Version of Trastuzumab Will Infringe “At Least” 40 Patents

    By James Love On November 17, 2017, Genentech, a subsidiary of the giant Swiss drug company Roche, together with City of Hope, a charity, filed a complaint in a U.S. District Court, seeking an injunction to block introduction of a Pfizer biosimilar version of Herceptin (INN: trastuzumab), as well as other remedies to infringement, including…

  • Read more: Save The Date! 2/22/18: The Jaharis Symposium on Health Law and Intellectual Property

    Save The Date! 2/22/18: The Jaharis Symposium on Health Law and Intellectual Property

    On February 22, 2018, join DePaul University, located in downtown Chicago, for The Jaharis Symposium on Health Law and Intellectual Property: Technological and Emergency Responses to Pandemic Diseases. Hosted by DePaul University’s Mary and Michael Jaharis Health Law Institute and the Center for Intellectual Property Law and Information Technology (CIPLIT®), this one day conference will focus on “best practices” in response…

  • Read more: REGISTER NOW (12/12)! Sixth Annual Health Law Year in P/Review

    REGISTER NOW (12/12)! Sixth Annual Health Law Year in P/Review

    Health Law Year in P/Review December 12, 2017 8:30 AM – 5:00 PM Wasserstein Hall, Milstein East AB Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Register for this event The Sixth Annual Health Law Year in P/Review symposium will feature leading experts discussing major developments during 2017 and what to watch out for in 2018. The…